Company Solutions

Kidney failure is among the most common and dangerous ICU complications.

Typically, kidney injury is detected relatively late, often after it is impossible to prevent further progression. We at Serenno are dedicated to reduce or even prevent this ICU complication by monitoring ongoing Urine Output (UO) to catch Acute Kidney Injury (AKI) earlier, making it easier to prevent, treat and save affected patients.

AKI is extremely common in the ICU and has no cure after onset. It is expensive to mitigate and has a yearly estimated death-toll of 300,000 lives in the US alone (tripling mortality).

The gold standard is lacking

Currently Urine Output is collected and calculated manually in ICUs around the world. It is the last metric still measured that way - once per hour, for every patient, 24/7. The lack of accurate, ongoing data is a large problem when trying to detect the early stages of Kidney failure and reduce or prevent it's devastating effects.

The Serenno solution

Serenno Medical is developing a novel method to monitor Urine Output, and so improve fluid balance and predict, identify, and avoid Acute Kidney Injury. The system is using a robust, hands-free, low cost and non-invasive method, allowing contact free monitoring for hospitalized patients. Using the system, the medical personnel would reduce their workload and exposure, be alerted to conditions requiring immediate attention, and able to predict and avoid AKI with no need for massive interventions. And so significantly reducing risk, LOS and costs.

The Serenno system was successfully tested in human clinical trials and is FDA approved, it is currently in mass production stages.

Looking For

Serenno Medical has received a $1.5M investment from a strategic investor (Q4 2020) and is now seeking to fill an additional $3M series A round, to be used for US market access, production ramp up, further clinical studies and R&D for the next generation devices.